Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.A221825 Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.A222078 The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.A221825, A221830 A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.A222078
INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1? mAbs Odesivimab (REGN 3471), Maftivimab (REGN 3479), and Atoltivimab (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV in vitro and protection against EBOV infection in vivo. INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.L17320
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Odesivimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Odesivimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Odesivimab. |
| Estrone | Estrone may increase the thrombogenic activities of Odesivimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Odesivimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Odesivimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Odesivimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Odesivimab. |
| Estriol | Estriol may increase the thrombogenic activities of Odesivimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Odesivimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Odesivimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Odesivimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Odesivimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Odesivimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Odesivimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Odesivimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Odesivimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Odesivimab. |
| Equol | Equol may increase the thrombogenic activities of Odesivimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Odesivimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Odesivimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Odesivimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Odesivimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Odesivimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Odesivimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Odesivimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Odesivimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Odesivimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Odesivimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Odesivimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Odesivimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Odesivimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Odesivimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Odesivimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Odesivimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Odesivimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Odesivimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Odesivimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Odesivimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Odesivimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Odesivimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Odesivimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Odesivimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Odesivimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Odesivimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Odesivimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Odesivimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Odesivimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Odesivimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Odesivimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Odesivimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Odesivimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Odesivimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Odesivimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Odesivimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Odesivimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Odesivimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Odesivimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Odesivimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Odesivimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Odesivimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Odesivimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Odesivimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Odesivimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Odesivimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Odesivimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Odesivimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Odesivimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Odesivimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Odesivimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Odesivimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Odesivimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Odesivimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Odesivimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Odesivimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Odesivimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Odesivimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Odesivimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Odesivimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Odesivimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Odesivimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Odesivimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Odesivimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Odesivimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Odesivimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Odesivimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Odesivimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Odesivimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Odesivimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Odesivimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Odesivimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Odesivimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Odesivimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Odesivimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Odesivimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Odesivimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Odesivimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Odesivimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Odesivimab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Odesivimab. |